pharma · Pancreatic Ductal Adenocarcinoma · Neuroendocrine Tumor Grade 2 · CATX
Perspective Therapeutics
Perspective Therapeutics patent portfolio — 1 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- Seattle, USA
- Founded
- 2023
- Employees
- 144
- Programs
- 6
- Drugs
- 1
- Patents
- 1
Perspective Therapeutics patents
1 pharmaceutical patents indexed for Perspective Therapeutics. 0 expire within 24 months.
Perspective Therapeutics has 1 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
Frequently asked questions
How many patents does Perspective Therapeutics have?
1 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Perspective Therapeutics patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.